Michael Morse, DPM
Foot & Ankle Surgery · Washington, DCNPI 1346245230
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $865 and has fallen 66.5% since, to $290 in 2025. That places this record below the midpoint for foot & ankle surgery clinicians in DC, where the typical reported total is $3,977.
Across 61 payments — averaging $45.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$455
- Kerecis Limited$348
- Bioventus LLC$269
- Amgen$210
- Convatec Inc.$170
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$148
- plus $1K from 21 others
What the payments were for
- Travel & lodging$211%
- Food & beverage$2,73299%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 14 | $455 |
| Kerecis Limited | 3 | $348 |
| Bioventus LLC | 3 | $269 |
| Amgen(2 entities) | 6 | $210 |
| Convatec Inc. | 3 | $170 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 3 | $148 |
| Melinta Therapeutics, LLC | 2 | $136 |
| Paratek Pharmaceuticals, Inc. | 1 | $119 |
| Triad Life Sciences Inc. | 1 | $112 |
| Biopro, Inc. | 1 | $105 |
| Ironshore Pharmaceuticals Inc. | 1 | $88 |
| Merck | 1 | $83 |
| Averitas Pharma Inc. | 4 | $78 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $78 |
| Nevro Corp. | 2 | $64 |
| Fidia Pharma USA Inc. | 2 | $41 |
| Osiris Therapeutics Inc. | 2 | $38 |
| Stryker | 2 | $36 |
| Sandoz | 1 | $27 |
| Solventum Corporation | 1 | $25 |
| Next Science LLC | 1 | $23 |
| Mimedx Group, Inc. | 1 | $21 |
| Sebela Pharmaceuticals Inc. | 1 | $19 |
| Organogenesis Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Arthrosurface Incorporated | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerecis Omega3 Marigen$731
- Kerecis Omega3 SurgiClose$709
- InnovaMatrix AC$237
- Kerecis Omega3 GraftGuide$192
- Exogen$132
- Exogen Ultrasound Bone Healing System$125
- Baxdela$125
- Santyl$122
- NUZYRA$119
- KRYSTEXXA$103
- LUZU$100
- JUBLIA$100
How this compares
$2,753 in reported general payments places this provider in the 40th percentile of 23 foot & ankle surgery providers in District of Columbia.
See all foot & ankle surgery providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JubliaEfinaconazole | 38 | $29,498 |
| Naftifine Hcl | 15 | $4,194 |
| Econazole Nitrate | 11 | $475 |
| Terbinafine Hcl | 16 | $336 |
| Doxycycline Hyclate | 20 | $134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia | $148 | $29,49838 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 23 foot & ankle surgery providers in District of Columbia.
Other foot & ankle surgery in Washington
- Paul CooperWashington$186K
- John SteinbergWashington$166K
- Ali Rahnama VaghefWashington$132K
- Jayson AtvesWashington$24K
- Shelton McKenzieWashington$22K
- Bilal LouzatiWashington$18K
- Ali QadriWashington$17K
- Alex MattiaWashington$13K
- Emily DurranceWashington$9K
- Selin RuggieriWashington$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.